Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 181 for moderate to severe Crohn's disease
NL-OMON39826Phase 2Active, not recruiting
- Sponsor
- Amgen
- Start
- Mar 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Crohn's disease and inflammatory bowel disease (IBD) comparing AMG 181 with Placebo (2 arms). Primary endpoint: CDAI remission at week 8. Started Mar 2013; status: active, not recruiting.
02
Drugs
abrilumab
03
Conditions
Crohn's diseaseinflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NL-OMON39826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39826.